Bangalore based start-up, Axio Biosolutions, a fast growing medtech company announced today that it has expanded its operations to UK. With this launch, Axio will be present in thirteen countries including Europe, Middle-East and Africa, reinforcing its commitment to address the unmet wound care challenges across the globe.

Funded by Accel Partners, IDG Ventures and GVFL, Axio is a global name that uses innovative medical technology to create breakthrough products and save people’s lives. Axio’s flagship product, Axiostat is an advanced wound management product that has received an overwhelming response from the time it was launched and is being successfully used by Military and para-military forces and emergency services world-over.

This 100% chitosan haemostatic dressing controls severe haemorrhage within minutes through its active adhesion to the trauma wound. The award winning and CE approved, Axiostat will be launched in UK market through The Emergency Services Show, scheduled on 21st and 22nd September 2016 and Trauma Innovation UK, which is Europe’s Largest Forum for military and emergency medicine scheduled on 27th and 28th September 2016.

Speaking on the occasion, Leo Mavely, CEO of Axio said, ‘Axiostat has been saving lives of accident victims and defense forces for many years now in India and world-over. We are delighted to expand our presence and bring Axiostat to UK & European Market. With our partner - Western Medical Supplies UK we expect to serve a large market, which has shown a lot of demand for effective haemostatic products.”

Uncontrolled bleeding is one of the leading causes of death from traumatic injuries. With growing number of accidents, increased conflicts, nascent or non-existent pre-hospital care, an effective haemostat has become an inevitable first-aid tool for emergency services across the globe.

Axiostat is regularly used by Indian Armed forces, BSF, NSG, and other para-military forces, as part of their defense kit, during their operations at the border and conflict zones such as North-East. The Axiostat dressing was famously used in the 2014 Russia-Ukraine conflict, which earned Axio global recognition.

Axio’s customers also include numerous government hospitals and reputed private institutions such as AIIMS, Manipal, Apollo, Breach Candy and Fortis. In the $1.7 billion global haemostat market, which is expected to become $2.5 billion by 2020, Axio today is a name to reckon with.

The company’s vision is to become the first choice for any customer looking for advanced, affordable wound care solutions worldwide. To make that happen, Axio has a fully functioning modern Research and Development (R&D) wing registered in Bangalore with a GMP, ISO 13485 manufacturing facility situated in Ahmedabad, Gujarat.

About Axio Biosolutions

Axio was founded in 2008 by Leo Mavely, a bioengineer to develop novel biopolymer platform based products for wound care. Axio has the distinction to be the first company from India to design, develop and commercialize an Emergency Haemostat for Trauma care. Vision of Axio is to develop affordable, high impact medical products that can solve unmet healthcare needs of emerging markets. Controlling life-threatening bleeding continues to be the major cause of death from traumatic injuries. Axiostat® is its flagship product developed to reduce the mortality due to traumatic bleeding. Axio is a ISO 13485 certified company with an experienced team focused on bringing high-impact medical products to markets world-over.

Funded by Accel Partners, IDG Ventures and GVFL, Axio is today a global name that uses innovative medical technology to create breakthrough products and save people’s lives. Axiostat is regularly used by Indian Armed forces, BSF, NSG, and other para-military forces, as part of their defense kit, during their operations at the border and conflict zones such as North-East. Axio’s customers also include numerous government hospitals and reputed private institutions such as AIIMS, Manipal, Apollo, Breach Candy and Fortis among others.